Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (151-160 of 193) with videos related to

Pageof 20
Sort By:
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Frontiers in Oncology|July 10, 2023
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignanciesFrancesco Angotzi, Marco Petrella, Tamara Berno, et al.
Hematological Oncology|July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Haematologica|February 24, 2022
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA studyIdanna Innocenti, Gianluigi Reda, Andrea Visentin, et al.
American Journal of Hematology|February 16, 2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor modelStefano Molica, Diana Giannarelli, Andrea Visentin, et al.
Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.
Cancers|July 2, 2021
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibFrancesca Romana Mauro, Diana Giannarelli, Andrea Visentin, et al.
Hemasphere|November 17, 2025
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)Luca De Carolis, Monia Capponi, Andrea Bernardelli, et al.
Cancers|June 29, 2019
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12Francesco Autore, Paolo Strati, Idanna Innocenti, et al.
Blood Advances|April 2, 2026
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12Luca Laurenti, Feliciana Guglielmi, Antonio Mosca, et al.
Pageof 20

Showing results (151-160 of 193) with videos related to

Sort By:
Pageof 20
Hematological Oncology|January 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohortEnrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, et al.
Frontiers in Oncology|July 10, 2023
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignanciesFrancesco Angotzi, Marco Petrella, Tamara Berno, et al.
Hematological Oncology|July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Haematologica|February 24, 2022
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA studyIdanna Innocenti, Gianluigi Reda, Andrea Visentin, et al.
American Journal of Hematology|February 16, 2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor modelStefano Molica, Diana Giannarelli, Andrea Visentin, et al.
Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.
Cancers|July 2, 2021
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibFrancesca Romana Mauro, Diana Giannarelli, Andrea Visentin, et al.
Hemasphere|November 17, 2025
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)Luca De Carolis, Monia Capponi, Andrea Bernardelli, et al.
Cancers|June 29, 2019
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12Francesco Autore, Paolo Strati, Idanna Innocenti, et al.
Blood Advances|April 2, 2026
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12Luca Laurenti, Feliciana Guglielmi, Antonio Mosca, et al.
Pageof 20